TITLE

Roche Kicks Off Review for Xenical Fat Drug

AUTHOR(S)
McMains, Andrew
PUB. DATE
April 2000
SOURCE
Adweek Eastern Edition;4/17/2000, Vol. 41 Issue 16, p4
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on Roche Laboratories has launched a review of the Xenical account at Lowe Consumer Healthcare. Creative and media duties in play; Potential side effects of Xenical.
ACCESSION #
3052315

 

Related Articles

  • Xenical set to debut weighty $75 mil campaign. Goetzl, David // Advertising Age;9/27/1999, Vol. 70 Issue 40, p1 

    The article reports on the planned advertising efforts for Hoffman-La Roche's anti-obesity drug Xenical. The company is set to launch its direct-to-consumer television campaign on October 4, 1999. Accompanying print work will run in weekly magazines. The campaign is from Lowe Consumer...

  • Xenical account moves to Y&R.  // Medical Marketing & Media;Aug2000, Vol. 35 Issue 8, p24 

    Reports that Hoffmann-La Roche has moved its account for Xenical to Y&R Advertising. Previous handling of the account by Lowe Consumer Healthcare; Awarding of the first professional promotion for Xenical to Sudler and Hennessey.

  • Xenical ads lack balance.  // Healthy Weight Journal;May/Jun2000, Vol. 14 Issue 3, p35 

    Deals with the letter made by the United States Food and Drug Administration (FDA) to Hoffman-LaRoche Inc. on the television advertisement of its Xenical or orlistat drug. FDA complaint on the advertisement's imbalances; Action taken by the company on the complaint.

  • Roche sheds Lowe as Xenical agency. Goetzl, David; Snyder Bulik, Beth // Advertising Age;4/17/2000, Vol. 71 Issue 17, p1 

    This article reports on the decision of Hoffman-La Roche to replace the Lowe Group as the advertising agency for weight loss drug Xenical in April 2000. The account for Xenical includes an estimated $80 million direct-to-consumer business as well as physician-targeted advertising. One hurdle...

  • Xenical endures ad silence as FDA forces alterations. Goetzl, David // Advertising Age;11/8/1999, Vol. 70 Issue 46, p40 

    This article reports on the changes made by U.S. drug company Hoffmann-La Roche to the direct-to-consumer advertising campaign for its obesity drug Xenical as of November 1999. The U.S. Food and Drug Administration (FDA) charged the commercial, valued at $70 million to $75 million, lacked fair...

  • FIRST CANADIAN TRIAL FOR XENICAL LAUNCHED.  // Worldwide Biotech;Mar2001, Vol. 13 Issue 3, p5 

    Reports that Hoffman-La Roche Limited has initiated a clinical trial to evaluate its weight loss medication Xenical in Canada.

  • Roche commits $75M to Xenical DTC campaign.  // Drug Store News;11/29/99, Vol. 21 Issue 19, p17 

    Discusses the launching of the television direct-to-consumer (DTC) program for Xenical, one of the largest DTC spends in the industry by Hoffman-La Roche Inc. Overview of the action taken by Hoffman to carry out the program; Role of the Indian Medical Society; Focus of the television campaigns.

  • Orlistat approved.  // Healthy Weight Journal;Sep/Oct1999, Vol. 13 Issue 5, p66 

    Reports on the approval of the drug orlistat from Roche Laboratories for the treatment of obesity. Efficacy of the drug; Side effects of the drug.

  • Xenical ad campaign planned.  // Medical Marketing & Media;Mar2001, Vol. 36 Issue 3, p24 

    Reports on the plans of Roche Laboratories to schedule the follow-up advertising campaign for Xenical. Inclusion of informational advertisements in the introductory campaign; Emphasis of the campaign on the health problem associated with overweight; Presentation on the side effects of the drug.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics